Please login to the form below

Not currently logged in
Email:
Password:

follicular lymphoma

This page shows the latest follicular lymphoma news and features for those working in and with pharma, biotech and healthcare.

BeiGene gets speedy US review for lymphoma drug zanubrutinib

BeiGene gets speedy US review for lymphoma drug zanubrutinib

The US regulator awarded the status for zanubrutinib as a second-line treatment for mantle cell lymphoma (MCL), an aggressive type of non-Hodgkin’s lymphoma for which the drug also ... It’s also in late-stage testing for chronic lymphocytic leukaemia

Latest news

  • Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

    First-in-class antibody drug conjugate. The FDA has approved Roche’s Polivy as part of the first chemo-immunotherapy combination for a B-cell lymphoma. ... Roche is also looking at combining Polivy with its CD20/CD3 bispecific antibody mosunetuzumab in

  • Regeneron's bispecific for lymphoma works in CAR-T failures Regeneron's bispecific for lymphoma works in CAR-T failures

    Regeneron has reported positive results with its REGN1979 drug in patients with non-Hodgkin’s lymphoma, including the evidence it can work in patients who have previously tried CAR-T therapies. ... rates in patients with relapsed or refractory diffuse

  • FDA begins speedy review of Celgene’s Revlimid combo in lymphoma FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

    R. 2. has the potential to offer patients with previously treated follicular lymphoma and marginal zone lymphoma a chemotherapy free option”, said Jay Backstrom, chief medical officer and Head of Global ... These results wildly contrasted to a previous

  • Regeneron’s early stage bispecific shows promise Regeneron’s early stage bispecific shows promise

    refractory (R/R) follicular lymphoma and diffuse large B-cell lymphoma (DLBCL), the two most common types of Non-Hodgkins Lymphoma (NHL). ... refractory follicular lymphoma patients," said Israel Lowy, M.D., Ph.D., Head of Clinical and Translational

  • Celgene’s Revlimid gets a win in late-stage lymphoma Celgene’s Revlimid gets a win in late-stage lymphoma

    The AUGMENT trial paired Revlimid (lenalidomide) with Roche’s established lymphoma therapy Rituxan (rituximab) in patient with two types of NHL – follicular lymphoma (FL) and marginal zone lymphoma (MZL) – and showed ... An earlier read-out in

More from news
Approximately 2 fully matching, plus 52 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics